The development of chimeric antigen receptor (CAR) T‐cell therapy for select hematological
malignancies represents one of the most remarkable therapeutic advances in the past …

The incidence of multiple myeloma is characterized by a steep increase with advancing age.
Dramatic improvements in survival have been reported in clinical trials; however, elderly …

Acute myeloid leukemia (AML) is marked by significant unmet clinical need due to both poor
survival and high relapse rates where long-term disease control for most patients with …

Advances in the understanding of disease biology, drug development, and supportive care
have led to improved outcomes in multiple myeloma. Given that these improvements have …

Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma
(MM). Population-based screening for MGUS could identify candidates for early treatment in …

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …

Machine learning can be used to make sense of healthcare data. Probabilistic machine
learning models help provide a complete picture of observed data in healthcare. In this …

Simple Summary Survival of patients with multiple myeloma continues to improve over time
in parallel with the development of new treatments. The combination of novel agents in the …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Hematologic malignancy outcomes have remarkably improved in the past decade with
further advancement expected in future years. However, the detrimental effects of financial …